Neutralization of multiple Staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats

Journal of Infectious Diseases

Volumn 198, Issue 3, 2008, Pages 344-348

  Yang, Xi ^a   Buonpane, Rebecca A ^a   Moza, Beenu ^b   Rahman, A K M Nur Ur ^c   Wang, Ningyan ^a   Schlievert, Patrick M ^d   McCormick, John K ^c   Sundberg, Eric J ^b   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TOXIC SHOCK SYNDROME TOXIN 1;

ANTIGEN BINDING; ARTICLE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTIGENS, BACTERIAL; BACTERIAL TOXINS; ENTEROTOXINS; RECEPTORS, ANTIGEN, T-CELL; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS;

EID: 48749096140     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/589776     Document Type: Article

References (15)

1. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55:77-104.
2. Boles JW, Pitt ML, LeClaire RD, et al. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol 2003; 108:51-9.
3. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 2005; 4:281-97.
4. Pang LT, Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor α secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infect Immun 2000; 68:3261-8.
5. Fleischer B, Necker A, Leget C, Malissen B, Romagne F. Reactivity of mouse T-cell hybridomas expressing human Vβ gene segments with staphylococcal and streptococcal superantigens. Infect Immun 1996; 64:987-94.
6. Buonpane RA, Moza B, Sundberg EJ, Kranz DM. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J Mol Biol 2005; 353:308 -21.
7. Buonpane RA, Churchill HR, Moza B, et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007; 13:725-9.
8. Rahman AK, Herfst CA, Moza B, et al. Molecular basis of TCR selectivity, cross-reactivity, and allelic discrimination by a bacterial superantigen: integrative functional and energetic mapping of the SpeC-Vβ2.1 molecular interface. J Immunol 2006; 177:8595-603.
9. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18:255-264.
10. Choi Y, Lafferty JA, Clements JR, et al. Selective expansion of T cells expressing Vβ 2 in toxic shock syndrome. J Exp Med 1990; 172:981-4.
11. Marrack P, Kappler J. The staphylococcal entertoxins and their relatives. Science 1990; 248:705-11.
12. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90:6444-8.
13. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17:251-72.
14. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-90.
15. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36.